Pages

Showing posts with label Penicillin binding protein. Show all posts
Showing posts with label Penicillin binding protein. Show all posts

ß-Lactams: Mechanisms of Action and Resistance

Beta-lactam antibiotics are typically used to treat a broad spectrum of Gram-negative bacteria. Beta-lactamases produced by Gram-negative organisms are usually secreted.This animation starts with the explanation of bacterial cell wall synthesis, the process targeted by ß-Lactams. Structurally, most bacteria consist of a cell membrane surrounded by a cell wall and, for some bacteria, an additional outer layer. Internal to the cell membrane is the cytoplasm which contains ribosomes, a nuclear region and in some cases granules and/or vesicles. Depending on the bacterial species, a number of different external structures may be found such as a capsule, flagella and pili.
Although the inhibitor-resistant β-lactamases are not ESBLs, they are often discussed with ESBLs because they are also derivatives of the classical TEM- or SHV-type enzymes. These enzymes were at first given the designation IRT for inhibitor-resistant TEM β-lactamase; however, all have subsequently been renamed with numerical TEM designations. There are at least 19 distinct inhibitor-resistant TEM β-lactamases. Inhibitor-resistant TEM β-lactamases have been found mainly in clinical isolates of E. coli, but also some strains of K. pneumoniae, Klebsiella oxytoca, P. mirabilis, and Citrobacter freundii. Although the inhibitor-resistant TEM variants are resistant to inhibition by clavulanic acid and sulbactam, thereby showing clinical resistance to the beta-lactam—lactamase inhibitor combinations of amoxicillin-clavulanate (co-amoxiclav), ticarcillin-clavulanate (co-ticarclav), and ampicillin/sulbactam, they normally remain susceptible to inhibition by tazobactam and subsequently the combination of piperacillin/tazobactam, although resistance has been described. To date, these beta-lactamases have primarily been detected in France and a few other locations within Europe.

Meropenem Animation

Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Mepem (Taiwan) Meropen (Japan, Korea) and Neopenem (India) . It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.
  Subscribe in a reader
Once Meropenam reaches Penicillin Binding Protein (PBPs) located at cytoplasm membrane it binds to them and interfere with their ability to create and modify peptidoglycan layer In PSEUDOMONAS AERUNGINOSA, Meropenam has a high affinity to the PBPII and PBPIII, this affinity is be lived to associate with high anti-pseudomonas activity has the result the cell wall weakens, osmotic pressure builds and cell ruptures and dies.
As a defense mechanism, bacteria develops resistance to antibiotics, the most common form of resistance to beta-lactam antibiotics is production of beta lactimases, enzymes that inactivate this antibiotics by breaking up the beta lactin rings.Merapenam retains high activity against PSEUDOMONAS AERUNGINOSA despite this organism inherent resistance to may drug classes. Studies have shown that Meropenam is not easily degrade by beta lactimases in the periplasmic space of Gram-negative Bacteria as other antibiotics. Merapenam has displayed significant stability to beta lactimases of most categories including penicillinases. Merapenam stability is believed to be link to 6alpha hydroxyl ethyl side chain on its chemical structure.